LivaNova PLC Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. LivaNova PLC is a global medical technology company operating two primary segments: Cardiopulmonary (heart-lung machines, oxygenators) and Neuromodulation (VNS Therapy for epilepsy and depression, sleep apnea devices). The filing includes revised financial data for prior periods to correct an immaterial classification error regarding employee costs in the Cardiopulmonary segment.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Net Revenue | $357.8 million | $318.1 million | $1,027.1 million | $931.6 million |
| Gross Profit | $244.9 million | $221.0 million | $700.1 million | $639.1 million |
| Operating Income | $54.0 million | $35.6 million | $156.8 million | $92.0 million |
| Net Income (Loss) | $26.8 million | $33.0 million | $(273.4) million | $7.3 million |
| Diluted EPS | $0.49 | $0.60 | $(5.01) | $0.13 |
| Cash & Equivalents | $646.1 million (as of Sept 30, 2025) | |||
| Total Debt Obligations | $434.5 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 12.5% in Q3 and 10.3% YTD compared to 2024. Cardiopulmonary revenue grew 18.0% in Q3, driven by the Essenz Perfusion System and consumables. Neuromodulation revenue grew 6.9% in Q3.
- SNIA Environmental Liability: The YTD net loss of $(273.4) million is primarily driven by a $363.8 million non-cash charge recorded in Q1 2025 following an Italian Supreme Court decision regarding environmental liabilities from the SNIA demerger. Q3 included a smaller interest accrual of $1.7 million.
- Debt Reduction: In May 2025, the Company repaid $200 million of Term Facilities, resulting in a $2.7 million loss on debt extinguishment. Total debt obligations decreased significantly from $627.6 million at year-end 2024 to $434.5 million.
- Expense Management: Operating expenses as a percentage of revenue declined. R&D expenses decreased due to cost reductions in the Depression Treatment (DTD) program. SG&A decreased due to lower cybersecurity incident costs and insurance recoveries.
Guidance, Outlook, and Risks
- Clinical Updates: The Company announced positive 12-month data from the OSPREY trial for the aura6000 sleep apnea system (65% responder rate). The RECOVER study for VNS Therapy in depression did not meet its primary endpoint for the unipolar cohort but showed secondary benefits; the Company is seeking CMS reconsideration for coverage.
- Legal Contingencies:
- SNIA Litigation: A current liability of $394.6 million is recorded. The case has been remanded to the Court of Appeal to implement the Supreme Court's decision. A hearing is scheduled for January 2026.
- 3T Heater-Cooler Litigation: Approximately 65 claims remain. The provision for these matters stands at $19.8 million.
- Cybersecurity: Direct costs totaled $13.1 million through Q3 2025. The Company has received $9.6 million in insurance reimbursements to date.
- Liquidity: The Company holds $646.1 million in cash and has $225.0 million available under its revolving credit facility. Management believes liquidity is sufficient for the next 12 months.
- Tax Legislation: The U.S. "One Big Beautiful Bill Act" (OBBBA) was enacted in July 2025, impacting the effective tax rate.
Investor Verification Checklist
- SNIA Liability Finality: Verify the outcome of the remanded proceedings in the Italian Court of Appeal scheduled for January 2026, as the $394.6 million liability is subject to further adjustment.
- Insurance Recoveries: Monitor the status of remaining insurance claims related to the 2023 cybersecurity incident to assess potential future cash inflows.
- 3T Litigation Exposure: Track the number of new claims and the adequacy of the $19.8 million provision given the ongoing nature of the product liability suits.
- Debt Maturity: Confirm the repayment strategy for the $56.7 million of 2025 Notes due in December 2025, noting that $57.5 million is currently designated for this purpose.
- Regulatory Approvals: Follow the progress of the CMS reconsideration request for VNS Therapy in treatment-resistant depression and the commercialization timeline for the aura6000 system.